鼠伤寒沙门菌耐药株拓扑异构酶基因突变分析

被引：2

作者：

郭云昌

裴晓燕

刘秀梅

机构：

[1] 中国疾病预防控制中心营养与食品安全所,中国疾病预防控制中心营养与食品安全所,中国疾病预防控制中心营养与食品安全所北京,北京,北京

来源：

卫生研究 | 2004年 / 05期

关键词：

鼠伤寒沙门菌; 拓扑异构酶; 突变;

D O I：

暂无

中图分类号：

R346 [];

学科分类号：

摘要：

目的　探讨鼠伤寒沙门菌对氟喹诺酮类药物的耐药性与拓扑异构酶基因突变之间的关系。方法　三株鼠伤寒沙门菌分离株X2 ,X7,X11对氟喹诺酮类药物环丙沙星的MIC分别为 32、0 38和 0 0 2 3μg ml,X2为耐药株。利用聚合酶链反应 (PCR)对其拓扑异构酶四个耐药基因gyrA ,gyrB ,parC ,和parE进行扩增和序列分析。结果　发现分离株X2的gyrA基因同时在 2 4 8、2 5 9位点发生点突变 (Ser83→Phe ,Asp87→Asn)。分离株X7gyrA基因在 2 4 8位点发生点突变 (Ser83→Tyr)。分离株X11的gyrA基因没有发生突变。X2parC基因QRDR在 2 38位点发生点突变 (Ser80→Arg)。而分离株X7、X11的parC基因没有发生突变。三株鼠伤寒沙门菌分离株的gyrB和parE基因都没有发现突变。结论　gyrA和parC上同时发生突变会导致鼠伤寒沙门菌对环丙沙星的高耐药性

引用

收藏

页码：591 / 594

页数：4

相关论文

共 9 条

[1]

Mutations in gyrA gene of quinolone-resistant salmonella serotypes isolated from humans and animals. Griggs DJ,Gensberg K,Piddock LJV. Antimicrobial Agents and Chemotherapy . 1996

[2]

Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong. Ling JM,Chan EM,Lam AW,et al. Antimicrobial Agents and Chemotherapy . 2003

[3]

A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium. Gensberg K,Jin YF,Piddock LJV. FEMS Microbiology Immunology . 1995

[4]

The Glu-84 of ParC subunit plays critical roles in both topoisomerase IV-quinolone and topoisomerase IV-DNA interactions. Hiasa H. Biochemistry . 2002

[5]

In vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gramnegative bacilli and Enterococcus faecalis. Tankovic J,Bachoual R,Ouabdesselam S,et al. Journal of Antimicrobial Chemotherapy . 1999

[6]

Alteration in the GyrA subunit of DNA gyrAse and ParC subunit of topoisomerase IV in quinoloneresistant clinical isolates of Klebsiella pneumoniae. Deguchi TA,Fukuoka M,Yasuda,et al. Antimicrobial Agents and Chemotherapy . 1997

[7]

gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Weigel LM,Steward CD,Tenover FC. Antimicrobial Agents and Chemotherapy . 1998

[8]

Cloning and nucleotide sequence of the DNA gyrase gyrA gene from Serratia marcescens and characterization of mutations in gyrA of quinolone-resistant clinical isolates. Kim JH,Cho EH,Kim KS,et al. Antimicrobial Agents and Chemotherapy . 1998

[9]

Genetic evidence for role of parC mutations in development of high-level fluoroquinolone resistance in escherichia coli. Heisig P. Antimicrobial Agents and Chemotherapy . 1996